Premium
Combination of carvacrol with simvastatin improves the lipid‐lowering efficacy and alleviates simvastatin side effects
Author(s) -
Abd El Aal Hayat A.,
Ahmed Lamiaa A.,
Hassan Wedad A.,
Fawzy Hala M.,
Moawad Helmy
Publication year - 2017
Publication title -
journal of biochemical and molecular toxicology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.526
H-Index - 58
eISSN - 1099-0461
pISSN - 1095-6670
DOI - 10.1002/jbt.21981
Subject(s) - simvastatin , chemistry , adiponectin , creatine kinase , endocrinology , lactate dehydrogenase , pharmacology , medicine , oxidative stress , hyperlipidemia , leptin , biochemistry , insulin , enzyme , diabetes mellitus , insulin resistance , obesity
Abstract The present investigation was designed to examine the possible additive hypolipidemic effect of carvacrol (CARV) in combination with simvastatin (SIM) on poloxamer 407 (P407)‐induced hyperlipidemia. Rats were injected with P407, (500 mg/ kg; i.p.), twice a week, for 30 days. Treatment was carried out by administration of SIM (20 mg/kg/day; p.o.) or CARV (50 mg/kg/day; p.o.) or combination of them. Treatment with CARV significantly decreased total cholesterol, triglycerides, low‐density lipoprotein, atherogenic index, leptin, and increased high‐density lipoprotein and adiponectin. Moreover, CARV potentiated the hypolipidemic effect of SIM. Both SIM and CARV alleviated the oxidative stress induced by P407. Interestingly, CARV, when combined with SIM, significantly ameliorated SIM‐induced liver and muscle injury by reducing the level of alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase, creatine kinase, and myoglobin and restoring the normal histological picture of both liver and muscle as well as apoptosis.